Published : 08 Jun 2022, 06:00 PM
Updated : 18 Jul 2022, 03:01 PM
The booster raised virus-neutralising antibodies by eight-fold in a study. The vaccine was generally well-tolerated, with side effects comparable to a booster dose of mRNA-1273 at the 50 micrograms level.
"We are submitting our preliminary data and analysis to regulators with the hope that the omicron-containing bivalent booster will be available in the late summer," Chief Executive Stephane Bancel said in a statement.
Share of Moderna was up 2% in premarket trading.